InsiderTrades.com logo
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Altcoin season moves fast, and those who hesitate are left behind. The window is closing.
>> Register for the Workshop Now

Malcolm Fairbairn Biography and Net Worth

Director of TFF Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Mr. Fairbairn was the Co-Founder, President and Chief Investment Officer for Ascend Capital, a multi-billion dollar Long-Short Equity fund for almost 20 years. In particular, he led vertically specialized teams that invested across all market sectors. Prior to Ascend, Mr. Fairbairn established a successful track record as a Managing Director for Citadel, LLC, and as a portfolio manager for Strome Susskind LLC.
Mr. Fairbairn holds an MBA from Harvard Business School and an MS and BS from MIT in Chemical Engineering.

What is Malcolm Fairbairn's net worth?

The estimated net worth of Malcolm Fairbairn is at least $55.32 as of November 11th, 2020. Mr. Fairbairn owns 851 shares of TFF Pharmaceuticals stock worth more than $55 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Fairbairn may own. Learn More about Malcolm Fairbairn's net worth.

How do I contact Malcolm Fairbairn?

The corporate mailing address for Mr. Fairbairn and other TFF Pharmaceuticals executives is 2600 Via Fortuna Suite 360, Austin TX, 78746. TFF Pharmaceuticals can also be reached via phone at 817-438-6168 and via email at [email protected]. Learn More on Malcolm Fairbairn's contact information.

Has Malcolm Fairbairn been buying or selling shares of TFF Pharmaceuticals?

Malcolm Fairbairn has not been actively trading shares of TFF Pharmaceuticals within the last three months. Most recently, on Wednesday, May 19th, Malcolm Fairbairn bought 400 shares of TFF Pharmaceuticals stock. The stock was acquired at an average cost of $223.75 per share, with a total value of $89,500.00. Learn More on Malcolm Fairbairn's trading history.

Who are TFF Pharmaceuticals' active insiders?

TFF Pharmaceuticals' insider roster includes Kirk Coleman (CFO), Malcolm Fairbairn (Director), and Glenn Mattes (CEO). Learn More on TFF Pharmaceuticals' active insiders.

Malcolm Fairbairn Insider Trading History at TFF Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2021Buy400$223.75$89,500.00
11/11/2020Sell2,533$398.25$1,008,767.25851View SEC Filing Icon  
See Full Table

Malcolm Fairbairn Buying and Selling Activity at TFF Pharmaceuticals

This chart shows Malcolm Fairbairn's buying and selling at TFF Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TFF Pharmaceuticals Company Overview

TFF Pharmaceuticals logo
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Read More

Today's Range

Now: $0.07
Low: $0.07
High: $0.07

50 Day Range

MA: $1.12
Low: $0.07
High: $2.51

2 Week Range

Now: $0.07
Low: $0.06
High: $11.00

Volume

N/A

Average Volume

461,491 shs

Market Capitalization

$288,795.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Altcoin season moves fast, and those who hesitate are left behind. The window is closing.
>> Register for the Workshop Now